Updates from #ASCO23: mRCC & the CONTACT03 Trial
Two Onc Docs
00:00
Analysis of the CONTACT03 Trial Outcomes in mRCC
Exploring the results of the CONTACT03 trial that compared a PDL-1 monoclonal antibody with cabozantinib versus cabozantinib alone in post immunotherapy for metastatic RCC, revealing similar progression-free survival and overall response rates in both arms.
Transcript
Play full episode
